Study Hints at Clinical Lab’s Future Role in Investigating Sudden Unexplained Death in Children

Why It Matters

The study could transform how clinical labs investigate unexplained child deaths, delivering faster, more comprehensive genetic answers and establishing long‑read sequencing as a standard diagnostic tool.

Key Takeaways

• Study uses PacBio HiFi long‑read sequencing as first‑line assay
• 200 SUDC trios will be sequenced to identify genetic causes
• Funding $328,133 over four years from SUDC Foundation
• Long‑read approach detects structural variants missed by short reads
• Labs must adopt advanced bioinformatics and trio analysis workflows

Pulse Analysis

Sudden Unexplained Death in Childhood remains a tragic mystery for many families, and traditional short‑read sequencing often fails to capture the full spectrum of genetic alterations that could explain these events. Structural variants, repeat expansions, and complex rearrangements are especially elusive, leaving clinicians without definitive answers. Long‑read technologies such as PacBio HiFi provide contiguous DNA reads that span these difficult regions, offering a more complete view of the genome and increasing the likelihood of pinpointing pathogenic changes.

The UW Medicine‑Seattle Children’s collaboration, backed by a $328,133 grant from the SUDC Foundation, will apply this technology to 200 trios—each consisting of a deceased child and both parents. By sequencing the entire genome with high accuracy and then phasing variants against parental data, researchers can differentiate inherited mutations from de novo events. This workflow demands sophisticated bioinformatics pipelines, robust variant interpretation frameworks, and close coordination with medical examiners, positioning clinical laboratories at the forefront of pediatric forensic genomics.

If successful, the project will set a precedent for integrating long‑read whole‑genome sequencing into routine post‑mortem investigations, potentially reshaping diagnostic standards across hospitals and reference labs. Families could receive clearer, faster explanations for their loss, while the broader medical community gains valuable data on the genetic architecture of SUDC. The ripple effect may accelerate adoption of long‑read platforms in other rare‑disease and newborn screening programs, driving market growth and spurring further innovation in genomic diagnostics.